The past 12 months mark Sphere Medical's transition from a promising technology platform into a commercial organisation. The receipt of the CE Mark has been followed by launches of Proxima 4 across several major European markets. An increasing number of hospitals have begun clinical evaluations, and the focus over the coming year is translating these expressions of interest into meaningful sales. Our valuation, based on a three-phase DCFbased model, remains unchanged at £30.2m, equivalent to 21.3p per share.
28 Feb 2017
2016 results highlight the progress achieved
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
2016 results highlight the progress achieved
Sphere Medical Holding (SPHR:LON) | 0 0 0.0% | Mkt Cap: 0.037m
- Published:
28 Feb 2017 -
Author:
Franc Gregori -
Pages:
8
The past 12 months mark Sphere Medical's transition from a promising technology platform into a commercial organisation. The receipt of the CE Mark has been followed by launches of Proxima 4 across several major European markets. An increasing number of hospitals have begun clinical evaluations, and the focus over the coming year is translating these expressions of interest into meaningful sales. Our valuation, based on a three-phase DCFbased model, remains unchanged at £30.2m, equivalent to 21.3p per share.